Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:23 AM
Ignite Modification Date:
2025-12-25 @ 4:23 AM
NCT ID:
NCT07263620
Eligibility Criteria:
Inclusion Criteria:
* Age ≥18 years and ≤80 years
* Pathologically confirmed diagnosis (via preoperative biopsy) of pancreatic cancer, gastric cancer, colorectal cancer, or esophageal cancer
* Imaging evaluation indicates borderline resectable or locally advanced disease, and the patient is scheduled to receive neoadjuvant therapy according to treatment guidelines
* Expected survival time \> 3 months
* Hematologic function: neutrophil count \> 1.5 × 10⁹/L
* Liver function:Total serum bilirubin ≤ 1.5 × upper limit of normal (ULN)；ALT and AST ≤ 2 × ULN
* Renal function: serum creatinine ≤ 1.5 × ULN
* No severe cardiovascular or cerebrovascular comorbidities and no psychiatric disorders
Exclusion Criteria:
* Physically unfit to undergo neoadjuvant chemotherapy
* Local recurrence or distant metastasis occurring within 1 month after surgery
* Impaired vital organ function, including but not limited to: Heart failure (NYHA Class III-IV); Myocardial infarction within the past 6 months; Severe arrhythmia; Respiratory failure
* Presence of another primary malignancy diagnosed within the past 5 years
* Pregnant or breastfeeding
* Inability to complete follow-up
* Active infection
* Severe constipation or sudden changes in bowel habits within the past 3 months
* Significant changes in dietary habits (e.g., meat-vegetable balance, meal timing, or frequency) within the past 3 months
* Medication history within the past 3 months including:Use of NSAIDs, immunosuppressants, antibiotics, traditional Chinese medicine, probiotics, or corticosteroids for ≥1 week; Use of proton pump inhibitors (PPIs) for more than 1 week within 1 month prior to sampling
* Refusal to sign the informed consent form
Sex:
ALL
Study:
NCT07263620
Study Brief:
Protocol Section:
NCT07263620